/UBX

UBX Stock - Unity Biotechnology, Inc.

Q: What is the analyst price target for UBX?

Analyst price target information is not currently available for UBX.

Q: What is UBX's market cap?

Market capitalization information is not currently available for UBX.

Healthcare|Biotechnology|NASDAQ

$0.20+92.77%

+$0.10 (+92.77%) • Jul 8

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+1149.4%upside

Target: $2.50

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for UBX

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.06

52W High$3.10

52W Low$0.10

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	$236,000	$4.78M	N/A
Gross Profit	$-867,000	$-19,699,000	$-1,944,000	$1.90M	$-3,449,000
Gross Margin	N/A	N/A	-823.7%	39.8%	N/A
Operating Income	$-31,171,000	$-44,667,000	$-57,572,000	$-56,665,000	$-91,334,000
Net Income	$-25,990,000	$-39,860,000	$-44,469,000	$-60,725,000	$-93,844,000
Net Margin	N/A	N/A	-18842.8%	-1269.3%	N/A
EPS	$-1.54	$-2.70	$-4.68	$-10.90	$-18.45

Company Overview

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

50%

Hold / Neutral

50%

Sell / Underperform

Analyst Consensus🟡 Mixed

2 Bullish2 Neutral/Bearish

Price Targets

Average Target

↑ 1774.1% Upside

Now

Low

Average

High

Based on 4 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
May 27th 2025	H.C. Wainwright	Downgrade	Neutral	$2
May 16th 2025	Mizuho	Downgrade	Neutral	$1← $6
August 22nd 2024	Rodman & Renshaw	Initiation	Buy	$8
November 16th 2023	Wedbush	Upgrade	Outperform	$4← $2

Earnings History & Surprises

UBX

Beat Rate

61%

Last 18 quarters

Avg Surprise

+13.3%

EPS vs Estimate

Beats / Misses

11/5

2 met exactly

Latest EPS

$-0.31

Q3 2025

EPS Surprise History

Q4 23

+23.0%

$-0.67vs$-0.87

Q1 24

+61.1%

$-0.28vs$-0.72

Q2 24

-10.4%

$-0.53vs$-0.48

Q3 24

+29.5%

$-0.31vs$-0.44

Q4 24

+5.0%

$-0.38vs$-0.40

Q1 25

+19.0%

$-0.34vs$-0.42

Q2 25

0.0%

$-0.43vs$-0.43

Q3 25

-3.3%

$-0.31vs$-0.30

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	Apr 20, 2026	—	—	—	—
Q4 2025	Nov 3, 2025	—	—	—	—
Q3 2025	Aug 5, 2025	$-0.30	$-0.31	-3.3%	✗ MISS
Q2 2025	Apr 22, 2025	$-0.43	$-0.43	0.0%	= MET
Q1 2025	Mar 7, 2025	$-0.42	$-0.34	+19.0%	✓ BEAT
Q4 2024	Nov 4, 2024	$-0.40	$-0.38	+5.0%	✓ BEAT
Q3 2024	Aug 6, 2024	$-0.44	$-0.31	+29.5%	✓ BEAT
Q2 2024	Apr 15, 2024	$-0.48	$-0.53	-10.4%	✗ MISS
Q1 2024	Mar 27, 2024	$-0.72	$-0.28	+61.1%	✓ BEAT
Q4 2023	Nov 13, 2023	$-0.87	$-0.67	+23.0%	✓ BEAT
Q3 2023	Aug 8, 2023	$-0.83	$-0.85	-2.4%	✗ MISS
Q2 2023	May 9, 2023	$-1.10	$-0.76	+30.9%	✓ BEAT
Q1 2023	Mar 15, 2023	$-1.15	$-1.00	+13.0%	✓ BEAT
Q4 2022	Nov 8, 2022	$-0.99	$-1.36	-37.4%	✗ MISS
Q3 2022	Aug 12, 2022	$-2.80	$-1.90	+32.1%	✓ BEAT
Q2 2022	May 10, 2022	$-2.60	$-2.80	-7.7%	✗ MISS
Q1 2022	Mar 15, 2022	$-3.10	$-1.80	+41.9%	✓ BEAT
Q4 2021	Nov 10, 2021	$-3.80	$-3.00	+21.1%	✓ BEAT
Q3 2021	Aug 10, 2021	$-3.20	$-3.20	0.0%	= MET
Q2 2021	May 11, 2021	$-3.80	$-2.90	+23.7%	✓ BEAT

Frequently Asked Questions about UBX

What is UBX's current stock price?

Unity Biotechnology, Inc. (UBX) is currently trading at $0.20 per share. The stock has moved +92.77% today.

What is the analyst price target for UBX?

The average analyst price target for UBX is $2.50, based on 1 analyst.

What sector is Unity Biotechnology, Inc. in?

Unity Biotechnology, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is UBX's market cap?

Unity Biotechnology, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.

Does UBX pay dividends?

No, Unity Biotechnology, Inc. does not currently pay a dividend to shareholders.